NCR Corp
Change company Symbol lookup
Select an option...
MTX Minerals Technologies Inc
NS-C NuStar Energy LP
DQ Daqo New Energy Corp
ITRI Itron Inc
PSA-I Public Storage
HSKA Heska Corp
SLGN Silgan Holdings Inc
DYNA Dynastar Holdings Inc
ELMWQ Electric Last Mile Solutions Equity Warrant Exp 24 Aug 2027 *W EXP 08/24/2027

Information Technology : Software | Small Cap Blend
Company profile

NCR Corporation is a software-and services-led enterprise technology provider that runs stores, restaurants and self-directed banking for its customers. Its segments include Payments & Network, Digital Banking, Self-Service Banking, Retail and Hospitality. The Payments & Network segment offers credit unions, banks, digital banks, fintech, stored-value debit card issuers, and other consumer financial services providers access to its retail-based automated teller machines (ATM) network. Digital Banking solution helps financial institutions implement their digital platform for various transactions. Its Self-Service Banking segment offers a line of ATM hardware and software, and related installation, maintenance, and managed and professional services. The Retail segment offers software-defined solutions to customers in the retail industry. Hospitality segment offers technology solutions, such as table-service, quick-service and fast-casual restaurants of all sizes to hospitality sector.

Closing Price
Day's Change
-0.40 (-2.06%)
B/A Size
Day's High
Day's Low

10-day average volume:

Seagen shares positive data for bladder cancer drug; stock is up 2.5%

7:30 am ET July 26, 2022 (MarketWatch)

Shares of Seagen Inc. (SGEN) gained 2.5% in premarket trading on Tuesday after the company said an early-stage clinical trial evaluating its investigational treatment for urothelial cancer in combination with Merck & Co. Inc.'s (MRK) Keytruda met its primary endpoint. Seagen is developing the therapy, enfortumab vedotin, with Astellas Pharma Inc. ; it received a Breakthrough Therapy designation in early 2020. The company said in a news release that the combination therapy generated a 64.5% confirmed objective response rate as a first-line treatment for patients with this type of locally advanced or metastatic bladder cancer. It also said the median duration of response was not met. Merck is reportedly in talks to buy Seagen for about $40 billion, according to media reports. Seagen's stock is up 11.8% so far this year, while the broader S&P 500 is down 16.7%.

-Jaimy Lee


(END) Dow Jones Newswires

July 26, 2022 07:30 ET (11:30 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.